U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311863) titled 'UGX202 Injection in Patients With Advanced Retinitis Pigmentosa' on Nov. 14, 2025.
Brief Summary: The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Retinitis Pigmentosa (RP)
Intervention:
GENETIC: UGX202 injection
Comparison of different dosages of UGX202
Recrui...